Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription
Elise Dréano, Pierre–Régis Burgel, Aurélie Hatton, et al.
European Respiratory Journal (2023) Vol. 62, Iss. 4, pp. 2300110-2300110
Closed Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Cystic fibrosis
Marcus Mall, Pierre–Régis Burgel, Carlo Castellani, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 24
Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rareCFTRvariants: a viewpoint
Pierre–Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon, et al.
European Respiratory Journal (2024) Vol. 63, Iss. 1, pp. 2301959-2301959
Closed Access | Times Cited: 19
Prime editing functionally corrects cystic fibrosis-causing CFTR mutations in human organoids and airway epithelial cells
Mattijs Bulcaen, Phéline Kortleven, Ronald B. Liu, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 5, pp. 101544-101544
Open Access | Times Cited: 16
The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
Pierre–Régis Burgel, Isabelle Sermet‐Gaudelus, Emmanuelle Girodon, et al.
The Lancet Respiratory Medicine (2024) Vol. 12, Iss. 11, pp. 888-900
Closed Access | Times Cited: 9
Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis
Isabelle Sermet‐Gaudelus, Sihem Benaboud, S. Bui, et al.
The Lancet (2024) Vol. 404, Iss. 10448, pp. 117-120
Closed Access | Times Cited: 6
Reported Adverse Events in a Multicenter Cohort of Patients Ages 6-18 Years with Cystic Fibrosis and at Least One F508del Allele Receiving Elexacaftor/Tezacaftor/Ivacaftor
Vito Terlizzi, Cristina Fevola, Santiago Presti, et al.
The Journal of Pediatrics (2024) Vol. 274, pp. 114176-114176
Closed Access | Times Cited: 6
Genetic surgery for a cystic fibrosis-causing splicing mutation
Mattijs Bulcaen, Marianne S. Carlon
Molecular Therapy — Methods & Clinical Development (2024) Vol. 32, Iss. 1, pp. 101177-101177
Open Access | Times Cited: 5
Unmet challenges in cystic fibrosis treatment with modulators
Federica Corrao, Mairead Kelly, Isabelle Sermet‐Gaudelus, et al.
Expert Review of Respiratory Medicine (2024) Vol. 18, Iss. 3-4, pp. 145-157
Closed Access | Times Cited: 5
Adenine Base Editing with engineered Virus-Like Particles rescues the CFTR mutation G542X in patient-derived intestinal organoids
L. Nicosia, Iwona Pranke, Ramón Latorre, et al.
iScience (2025) Vol. 28, Iss. 3, pp. 111979-111979
Open Access
The apical mucus layer alters the pharmacological properties of the airway epitheliumy
Daniela Guidone, Martina De Santis, Emanuela Pesce, et al.
The Journal of Physiology (2025)
Open Access
First real-world study of fetal therapy with CFTR modulators in cystic fibrosis: Report from the MODUL-CF study
Anne-Marie Bonnel, Tiphaine Bihouée, Mélanie Ribault, et al.
Journal of Cystic Fibrosis (2025)
Closed Access
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor
Vito Terlizzi, Miquéias Lopes‐Pacheco
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access
Cystic fibrosis: a model for research and management of respiratory diseases
Almudena Felipe Montiel, Antonio Álvarez Fernández, Àlvar Agustí, et al.
Therapeutic Advances in Respiratory Disease (2025) Vol. 19
Open Access
Recent developments in cystic fibrosis drug discovery: where are we today?
Miquéias Lopes‐Pacheco, Amanda Winters, JaNise J. Jackson, et al.
Expert Opinion on Drug Discovery (2025)
Closed Access
Laboratory Tools to Predict CFTR Modulator Therapy Effectiveness and to Monitor Disease Severity in Cystic Fibrosis
Mafalda Bacalhau, Mariana Camargo, Miquéias Lopes‐Pacheco
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 93-93
Open Access | Times Cited: 4
Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy
Naïm Bouazza, Saı̈k Urien, Frantz Foissac, et al.
Clinical Pharmacokinetics (2024) Vol. 63, Iss. 3, pp. 333-342
Closed Access | Times Cited: 4
Evaluation of the response to elexacaftor-tezacaftor-ivacaftor of the rare CFTR variants L383S, I507del, L1065P and R1066H in intestinal organoid-derived epithelial monolayers
Jessica Conti, Dora Angyal, Karina Kleinfelder, et al.
Journal of Cystic Fibrosis (2025)
Open Access
Traitements de la mucoviscidose
Emmanuelle Bardin, Iwona Pranke, Alexandre Hinzpeter, et al.
médecine/sciences (2024) Vol. 40, Iss. 3, pp. 258-267
Open Access | Times Cited: 3
Gene editing flows to the lungs
Mattijs Bulcaen, Marianne S. Carlon
Science (2024) Vol. 384, Iss. 6701, pp. 1175-1176
Closed Access | Times Cited: 3
Cystic fibrosis year in review 2023
David V. Swetland, Adrienne P. Savant
Pediatric Pulmonology (2024) Vol. 59, Iss. 12, pp. 3106-3116
Open Access | Times Cited: 3
Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme
Pierre–Régis Burgel
European Respiratory Journal (2024) Vol. 63, Iss. 2, pp. 2400233-2400233
Closed Access | Times Cited: 2
Effect of CFTR Modulators on Oxidative Stress and Autophagy in Non-CFTR-Expressing Cells
Filippo Scialò, Gustavo Cernera, Lorenza Polise, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 19, pp. 10360-10360
Open Access | Times Cited: 2
ERJ2024: your journal, my journal, our journal
Don D. Sin, James D. Chalmers
European Respiratory Journal (2024) Vol. 63, Iss. 1, pp. 2302215-2302215
Open Access | Times Cited: 1
Beyond Kaftrio : mechanistic insights to maximize N1303K-CFTR rescue
Iwona Pranke, Valeria Capurro, B. Chevalier, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Precision medicine in cystic fibrosis: predictive role of forskolin-induced swelling assay
Eva Fürstová, Pavel Dřevı́nek, S. Novotna, et al.
European Respiratory Journal (2024) Vol. 63, Iss. 4, pp. 2400156-2400156
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top